The COAGADEX Copay Support Program

If you have a prescription for COAGADEX and are having difficulty paying for your medication, BPL may be able to help.

  • The COAGADEX Copay Support Program will provide up to $12,000 per calendar year to cover your out-of-pocket expenses for your COAGADEX prescription. Some restrictions apply — see below for more information.
  • The COAGADEX Copay Support Program is easy to use, with no cards required. To see if you qualify:

    Please visit

    Physicians or Pharmacists:
    Please visit

Rules and eligibility

  1. The COAGADEX Copay Support Program is for patients who have a valid prescription for COAGADEX regardless of financial need
  2. The program is valid for out-patient use only
  3. Not valid for prescriptions reimbursed by Medicaid, Medicare, VA, TRICARE, or any other federal or state healthcare programs
  4. Not valid where prohibited by health insurance provider or by law
  5. Non-medication expenses, such as ancillary infusion supplies, are not eligible
  6. BPL reserves the right to rescind, revoke, or change the program rules at any time, in whole, or in part at any time without notice

Please visit for full rules and eligibility.

Indications and Usage for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

Limitation of Use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.

Contraindication for COAGADEX

COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.

Important Safety Information for COAGADEX

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ‚Č•5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.